Target- |
Mechanism- |
|
|
Active Indication- |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.GB |
First Approval Date31 Dec 2009 |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.GB |
First Approval Date31 Dec 2009 |
|
MechanismNK1R antagonists |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date26 Mar 2003 |
Relative Bioavailability of NXP001 Compared to Emend® in Healthy Volunteers
This study will compare the relative bioavailability of both an oral capsule formulation and an oral suspension formulation of NXP001 to Emend® in healthy male volunteers in the fasted state.
100 Clinical Results associated with Nuformix Technologies Ltd.
0 Patents (Medical) associated with Nuformix Technologies Ltd.
100 Deals associated with Nuformix Technologies Ltd.
100 Translational Medicine associated with Nuformix Technologies Ltd.